4.6 Article

Comparing Care for Breast Cancer Survivors to Non-Cancer Controls: A Five-Year Longitudinal Study

期刊

JOURNAL OF GENERAL INTERNAL MEDICINE
卷 24, 期 4, 页码 469-474

出版社

SPRINGER
DOI: 10.1007/s11606-009-0903-2

关键词

breast cancer; preventive care; survivorship

资金

  1. American Cancer Society

向作者/读者索取更多资源

Deficiencies in care for cancer survivors may result from unclear roles for primary care providers (PCPs) and oncology specialists in follow-up. To compare cancer survivors' care to non-cancer controls. Retrospective, longitudinal, controlled study starting 366 days post-diagnosis. Stage 1-3 breast cancer survivors age 65+ diagnosed in 1998 (n = 1961) and matched non-cancer controls (n = 1961). Using the SEER-Medicare database, we examined the number of visits to PCPs, oncology specialists, and other physicians; receipt of influenza vaccination, cholesterol screening, colorectal cancer screening, bone densitometry, and mammography; and whether care receipt was associated with physician mix visited. Survivors were consistently less likely to receive influenza vaccination, cholesterol screening, colorectal cancer screening, and bone densitometry but more likely to receive mammograms than controls (all p < 0.05). Over time, colorectal cancer screening and mammography decreased and influenza vaccination increased for both groups (all p < 0.0001). Trends over time in care receipt were similar for survivors and controls. In Year 1, survivors had more visits to PCPs but fewer visits to other physicians than controls (both p < 0.05). Over time, survivors' visits to PCPs and other physicians increased and to oncology specialists decreased (all p < 0.0001). Controls' visits to PCPs increased (p < 0.0001) faster than survivors' (p = 0.003). Controls' visits to other physicians increased (p < 0.0001) at a rate similar to survivors. Survivors who visited both a PCP and oncology specialist were most likely to receive each service. Better coordination between PCPs and oncology specialists may improve care for older breast cancer survivors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Ophthalmology

Establishing a method to estimate the effect of antimyopia management options on lifetime cost of myopia

Tim R. Fricke, Padmaja Sankaridurg, Thomas Naduvilath, Serge Resnikoff, Nina Tahhan, Mingguang He, Kevin D. Frick

Summary: This study describes a methodology for estimating lifetime myopia costs and compares different management options in the context of Australia and China. The results suggest that investing in active myopia management can lead to economic balance or even better outcomes by reducing refractive progression, using simpler lenses, and minimizing the risk of pathology and vision loss.

BRITISH JOURNAL OF OPHTHALMOLOGY (2023)

Article Oncology

Improving biobehavioral health in younger breast cancer survivors: Pathways to Wellness trial secondary outcomes

Julienne E. Bower, Ann H. Partridge, Antonio C. Wolff, Steve W. Cole, Michael R. Irwin, Elissa D. Thorner, Hadine Joffe, Laura Petersen, Catherine M. Crespi, Patricia A. Ganz

Summary: This study examined the effects of interventions on younger breast cancer survivors and found that mindful awareness practices (MAPs) had beneficial effects on psychological and immune outcomes, indicating its potential for enhancing biobehavioral health.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Article Oncology

Clinicopathologic and sociodemographic factors associated with late relapse triple negative breast cancer in a multivariable logistic model: A multi-institution cohort study

Adith Abraham, Carlos H. Barcenas, Richard J. Bleicher, Adam L. Cohen, Sara H. Javid, Ellis G. Levine, Nancy U. Lin, Beverly Moy, Joyce C. Niland, Antonio C. Wolff, Michael J. Hassett, Sarah Asad, Daniel G. Stover

Summary: We developed a risk prediction model for late relapse of triple negative breast cancer (lrTNBC) using clinicopathologic and sociodemographic features. Our study found that tumor stage at diagnosis and BMI were significantly associated with lrTNBC. This risk prediction model may help identify patients at risk of developing lrTNBC and should be further investigated.

BREAST (2023)

Article Oncology

Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial

Kala Visvanathan, Leslie Cope, Mary Jo Fackler, Michael Considine, Lori Sokoll, Lisa A. Carey, Andres Forero-Torres, James N. Ingle, Nancy U. Lin, Rita Nanda, Anna Maria Storniolo, Suzana Tulac, Neesha Venkatesan, Natalie C. Wu, Sudhakar Marla, Scott Campbell, Michael Bates, Christopher B. Umbricht, Antonio C. Wolff, Saraswati Sukumar

Summary: This study evaluated the clinical utility of a novel liquid biopsy-breast cancer methylation (LBx-BCM) prototype assay for early assessment of disease progression in women with metastatic breast cancer (MBC). The results showed that high levels of cumulative methylation (CM) were associated with shorter median progression-free survival (PFS) and overall survival (OS) at week 4. The CM levels at week 4 could be used to predict disease progression as early as 3 months after initiating a new treatment.

CLINICAL CANCER RESEARCH (2023)

Editorial Material Oncology

Antibody-Drug Conjugates in Breast Cancer: Searching for Magic Bullets

Cesar A. Santa-Maria, Antonio C. Wolff

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Racial and ethnic disparities in mortality among breast cancer survivors after a second malignancy

Zhengyi Deng, Miranda R. Jones, Mei-Cheng Wang, Antonio C. Wolff, Kala Visvanathan

Summary: Higher cancer mortality was observed among Non-Hispanic Black and Hispanic survivors, while higher cardiovascular mortality was observed among Non-Hispanic Black survivors among women who survive a first breast cancer to develop a second primary cancer.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Article Oncology

Evaluating potential overuse of surveillance care in cancer survivors

Jennifer Y. Sheng, Claire F. Snyder, Katherine C. Smith, Jennifer DeSanto, Nancy Mayonado, Susan Rall, Sharon White, Amanda L. Blackford, Fabian M. Johnston, Robert L. Joyner, Joan Mischtschuk, Kimberly S. Peairs, Elissa Thorner, Phuoc T. Tran, Antonio C. Wolff, Youngjee Choi

Summary: Survivorship care plans (SCPs) are important for communicating cancer-related information. This study found that some tests conducted after SCP receipt were not consistent with guidelines, indicating overuse. This analysis identifies areas for improvement in guideline-concordant care.

CANCER MEDICINE (2023)

Article Oncology

Oncologist-Reported Barriers and Facilitators to Enrolling Patients in Optimization Trials That Test Less Intense Cancer Treatment

Gabrielle B. Rocque, Courtney Andrews, Valerie M. Lawhon, Rachel Frazier, Stacey A. Ingram, Mary Lou Smith, Lynne I. Wagner, Lisa Zubkoff, Nadine Tung, Lauren P. Wallner, Antonio C. Wolff

Summary: As outcomes improve in early-stage breast cancer, clinical trials are shifting towards optimization trials, which aim to use less toxic therapy while maintaining survival outcomes. However, little is known about physician perspectives on the barriers and facilitators to enrollment in these trials and the generalizability of the results.

JCO ONCOLOGY PRACTICE (2023)

Article Oncology

Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis

Susana L. Garcia-Recio, Toshinori J. Hinoue, Gregory L. C. Wheeler, Benjamin J. Kelly, Ana C. A. Garrido-Castro, Tomas Pascual, Aguirre A. M. De Cubas, Youli B. Xia, Brooke M. Felsheim, Marni B. McClure, Andrei A. Rajkovic, Ezgi Karaesmen, Markia A. Smith, Cheng E. Fan, Paula I. Gonzalez J. Ericsson, Melinda E. Sanders, Chad J. Creighton, Jay T. Bowen, Kristen Leraas, Robyn T. Burns, Sara Coppens, Amy L. Wheless, Salma S. Rezk, Amy L. K. Garrett, Joel S. Parker, Kelly K. H. Foy, Hui Shen, Ben H. Park, Ian Krop, Carey F. Anders, Julie Gastier-Foster, Mothaffar F. U. Rimawi, Rita Nanda, Nancy U. Lin, Claudine Isaacs, P. Kelly J. Marcom, Anna Maria Storniolo, Fergus J. Couch, Uma Chandran, Michael Davis, Jonathan C. Silverstein, Alexander G. Ropelewski, Minetta C. Liu, Susan G. L. Hilsenbeck, Larry Norton, Andrea L. C. Richardson, W. Fraser E. Symmans, Antonio C. A. Wolff, Nancy E. V. Davidson, Lisa A. M. Carey, Adrian V. A. Lee, Justin M. W. Balko, Katherine A. R. Hoadley, Peter W. A. Laird, Elaine R. A. Mardis, Tari A. A. King, Charles M. AURORA US Network, Charles M. Perou

Summary: The AURORA US Metastasis Project aimed to identify molecular features associated with metastasis in breast cancer. By analyzing the samples from 55 females with metastatic breast cancer, changes in gene expression subtypes and DNA clonality shifts were observed. Downregulation of estrogen receptor (ER)-mediated cell-cell adhesion genes through DNA methylation mechanisms was observed in metastases. Differences in the tumor microenvironment and immune cell infiltrates were also found in different breast cancer subtypes, providing implications for targeted therapies.

NATURE CANCER (2023)

Review Oncology

Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials

Laura Pala, Tommaso De Pas, Eleonora Pagan, Isabella Sala, Chiara Catania, Emma Zattarin, Paolo Arnone, Massimo M. Grassi, Marco Colleoni, Antonio C. Wolff, Javier Cortes, Martine Piccart, Richard D. Gelber, Giuseppe Viale, Vincenzo Bagnardi, Fabio Conforti

Summary: This study conducted a systematic review and meta-analysis of randomized clinical trials to compare the efficacy of limited-extended adjuvant endocrine treatment (ET) and full-extended ET in patients with early-stage breast cancer. The results showed that full-extended ET significantly improved disease-free survival (DFS) in patients with nodal-positive disease, while no significant improvement was observed in other subgroups.

BREAST (2023)

Article Oncology

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update

Antonio C. Wolff, Mark R. Somerfield, Mitchell Dowsett, M. Elizabeth H. Hammond, Daniel F. Hayes, Lisa M. McShane, Thomas J. Saphner, Patricia A. Spears, Kimberly H. Allison

Summary: This article is an update on the recommendations for HER2 testing in breast cancer, affirming the 2018 ASCO-CAP recommendations. The article emphasizes a new indication for trastuzumab deruxtecan when HER2 is not overexpressed or amplified, and provides best practice recommendations to distinguish IHC 0 and 1+.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Editorial Material Oncology

Flashback Foreword: Multigene Predictor for Chemotherapy Response in Breast Cancer

Antonio C. Wolff

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Evaluation of Predict, a prognostic risk tool, after diagnosis of a second breast cancer

Zhengyi Deng, Miranda R. Jones, Antonio C. Wolff, Kala Visvanathan

Summary: The UK National Health Service's Predict tool performs well in predicting breast cancer-specific mortality for first breast cancer, but underestimates it for second breast cancer, especially for estrogen receptor-positive breast cancer patients.

JNCI CANCER SPECTRUM (2023)

Article Oncology

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial

Sara M. Tolaney, Paolo Tarantino, Noah Graham, Nabihah Tayob, Laia Pare, Guillermo Villacampa, Chau Dang, Denise A. Yardley, Beverly Moy, P. Kelly Marcom, Kathy S. Albain, Hope S. Rugo, Matthew J. Ellis, Iuliana Shapira, Antonio C. Wolff, Lisa A. Carey, Romualdo Barroso-Sousa, Patricia Villagrasa, Michelle DeMeo, Molly DiLullo, Jorge Gomez Tejeda Zanudo, Jakob Weiss, Nikhil Wagle, Ann H. Partridge, Adrienne G. Waks, Clifford A. Hudis, Ian E. Krop, Harold J. Burstein, Aleix Prat, Eric P. Winer

Summary: This study reports the long-term outcomes of patients with small, node-negative, HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab, and establishes potential biomarkers to predict prognosis. The results indicate that adjuvant paclitaxel and trastuzumab is a reasonable treatment standard for this population, and the HER2DX genomic tool might help refine the prognosis.

LANCET ONCOLOGY (2023)

暂无数据